Home › Companies › IRD

Opus Genetics

IRD Rare disease Lead: Approved 3 Biotech Distilled articles ↓

Ophthalmology Gene Therapy Small Molecule

Most recent annual filing: 2026-03-15

Catalyst timeline

7 trackedQuarter catalyst calendar →

OPGx-BEST1 toplineSep 2026OPGx-BEST1 topline, Sep 2026, thesis-defining
OPGx-LCA5 Ph3 start4Q 2026OPGx-LCA5 Ph3 start, 4Q 2026, routine
OPGx-RDH12 trial start4Q 2026OPGx-RDH12 trial start, 4Q 2026, routine
Phentolamine Ophthalmic Solution 0.75% PSOct 17, 2026Phentolamine Ophthalmic Solution 0.75% PS, Oct 17, 2026, material
OPGx-MERTK trial start1Q 2027OPGx-MERTK trial start, 1Q 2027, routine
OPGx-RHO trial start2H 2027OPGx-RHO trial start, 2H 2027, routine
OPGx-LCA5 corporate updateMar 31, 2028OPGx-LCA5 corporate update, Mar 31, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (14 active programs)

OPGx-LCA5

Gene Therapy Target: LCA5

Leber Congenital Amaurosis Phase 3 Phase 1/2 trial subretinal University of Pennsylvania

OPGx-BEST1

Gene Therapy Target: BEST1

Best Vitelliform Macular Dystrophy Phase 1 Phase 1/2 trial subretinal NCT07185256
Autosomal Recessive Bestrophinopathy Phase 1 Phase 1/2 trial subretinal NCT07185256

OPGx-RHO

Gene Therapy Target: RHO

Retinitis Pigmentosa Preclinical

OPGx-RDH12

Gene Therapy Target: RDH12

Leber Congenital Amaurosis Preclinical NCT07681778
Retinal Dystrophy

OPGx-MERTK

Gene Therapy Target: MERTK

Retinitis Pigmentosa Preclinical Cleveland Clinic Abu Dhabi
Retinal Dystrophy

OPGx-NMNAT1

Gene Therapy Target: NMNAT1

Leber Congenital Amaurosis Preclinical

OPGx-CNGB1

Gene Therapy Target: CNGB1

Retinitis Pigmentosa Preclinical

RYZUMVI

phentolamine ophthalmic solution 0.75% · phentolamine mesylate

Small Molecule Target: alpha-1 adrenergic receptor, alpha-2 adrenergic receptor

Pharmacologically Induced Mydriasis Approved topical Viatris

RYZUMVI

phentolamine ophthalmic solution 0.75%

Small Molecule Target: alpha-1 adrenergic receptor, alpha-2 adrenergic receptor

Presbyopia NDA Submitted topical Viatris
Vision Disturbances After Keratorefractive Surgery Phase 3 topical Viatris

APX3330

Small Molecule Target: APE1/Ref-1

Diabetic Retinopathy Phase 2 oral

Biotech Distilled coverage (3)

2026-08-07 UPDATE: Opus Genetics (IRD) - The September Date Is Back On 🔒 Paid
2026-08-04 UPDATE: Opus Genetics (IRD) - The Registrational Trial Is Full 🔒 Paid
2026-06-17 Opus Genetics (IRD) — Scientific Deep Dive for OPGx-LCA5, OPGx-BEST1, and the IRD Gene Therapy Pipeline

Articles open on Substack. Some deep dives are subscriber-only.